- Home
- MIMI vs AARD Comparison
MIMI vs AARD Comparison
Compare MIMI & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIMI
- AARD
- Stock Information
- Founded
- MIMI 2018
- AARD 2017
- Country
- MIMI Hong Kong
- AARD United States
- Employees
- MIMI N/A
- AARD N/A
- Industry
- MIMI
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- MIMI
- AARD Health Care
- Exchange
- MIMI NYSE
- AARD Nasdaq
- Market Cap
- MIMI 139.9M
- AARD 154.9M
- IPO Year
- MIMI 2025
- AARD 2025
- Fundamental
- Price
- MIMI $4.31
- AARD $10.42
- Analyst Decision
- MIMI
- AARD Strong Buy
- Analyst Count
- MIMI 0
- AARD 4
- Target Price
- MIMI N/A
- AARD $31.50
- AVG Volume (30 Days)
- MIMI 34.0K
- AARD 68.3K
- Earning Date
- MIMI 01-01-0001
- AARD 01-01-0001
- Dividend Yield
- MIMI N/A
- AARD N/A
- EPS Growth
- MIMI N/A
- AARD N/A
- EPS
- MIMI 0.04
- AARD N/A
- Revenue
- MIMI $4,248,548.00
- AARD N/A
- Revenue This Year
- MIMI N/A
- AARD N/A
- Revenue Next Year
- MIMI N/A
- AARD N/A
- P/E Ratio
- MIMI $118.11
- AARD N/A
- Revenue Growth
- MIMI 63.94
- AARD N/A
- 52 Week Low
- MIMI $3.36
- AARD $4.88
- 52 Week High
- MIMI $6.84
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- MIMI N/A
- AARD N/A
- Support Level
- MIMI N/A
- AARD N/A
- Resistance Level
- MIMI N/A
- AARD N/A
- Average True Range (ATR)
- MIMI 0.00
- AARD 0.00
- MACD
- MIMI 0.00
- AARD 0.00
- Stochastic Oscillator
- MIMI 0.00
- AARD 0.00
About MIMI MINT INCORPORATION LIMITED
Mint Inc Ltd is a Hong Kong-based interior design and fit-out works provider. It strategically focuses on providing integrated and industry-specific interior design and fit-out works for commercial properties. The company's work encompasses offices of different industries and various kinds of retail stores to reflect its customers' corporate values and conceptualize its customers' brands. Its commercial projects cover internationally-renowned retail stores, food and beverage outlet chains, offices, and other premises of a charitable organization in Hong Kong. It also provides integrated interior design and fit-out works for luxury residential properties to enhance the interior space's aesthetics and functionality.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.